Prescient Therapeutics Limited
Research Prescient Therapeutics Limited (PTX.AX) on Bullrun: market cap AUD 66.34M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPTX.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 66.34M
- Financial periodFY2026
- Net income-AUD 7.00M
- Free cash flow-AUD 7.22M
Valuation Snapshot
latest market cap is AUD 66.34M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | -AUD 7.00M | -AUD 7.22M | n/a | -0.01 | AUD 9.03M | AUD 222.97K | AUD 14.20M |
| FY2025 | n/a | -AUD 7.32M | -AUD 7.24M | n/a | -0.01 | AUD 6.91M | n/a | AUD 11.39M |
| FY2024 | n/a | -AUD 8.24M | -AUD 7.40M | n/a | -0.01 | AUD 10.49M | AUD 330.49K | AUD 18.07M |
| FY2023 | n/a | -AUD 7.00M | -AUD 6.19M | n/a | -0.01 | AUD 5.90M | n/a | AUD 26.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 66.34M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company is also developing cell therapy platforms, including CellPryme, a high-performance cell therapy enhancement platform;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Prescient Therapeutics Limited's market cap?
Prescient Therapeutics Limited's market capitalization is AUD 66.34M.
What does Prescient Therapeutics Limited do?
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company is also developing cell therapy platforms, including CellPryme, a high-performance cell therapy enhancement platform; and OmniCAR, is a platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability.